Multi-System
Also called Hutchinson-Gilford progeria syndrome, HGPS
Progeria (Hutchinson-Gilford progeria syndrome, HGPS) is an extraordinarily rare autosomal dominant disorder caused by a point mutation (c.1824C>T) in the LMNA gene occurring de novo in almost all cases.
About trials for Progeria
Clinical trials for progeria have evaluated farnesyltransferase inhibitors (lonafarnib), which showed modest benefit in slowing cardiovascular disease progression in early trials. The Progeria Research Foundation maintains information on clinical trials and provides support for affected families.
Try Match Me →Autosomal dominant disorder, almost always due to de novo LMNA mutations. Median age of death about 13-14 years, usually from myocardial infarction or stroke. No ethnic predisposition. Affects males and females equally.
Clinical trials for progeria have evaluated farnesyltransferase inhibitors (lonafarnib), which showed modest benefit in slowing cardiovascular disease progression in early trials. The Progeria Research Foundation maintains information on clinical trials and provides support for affected families. Current management is symptomatic, focusing on cardiovascular risk factor management and monitoring for complications. Recent drug combinations including lonafarnib have shown improved efficacy. Research into progeria has provided valuable insights into aging and cardiovascular disease. Discuss with your cardiologist and geneticist about clinical trial eligibility and emerging therapies that might extend lifespan and quality of life.
Sarcoidosis is an inflammatory disease characterized by formation of granulomas (clusters of immune cells) in multiple o...
Tuberous sclerosis is an autosomal dominant genetic disorder caused by mutations in TSC1 or TSC2 genes, resulting in dys...
Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring t...